摘要
目的探讨非霍奇金淋巴瘤(NHL)患者在自体干细胞移植(ASCT)前后18F-脱氧葡萄糖(FDG)正电子发射计算机断层扫描(PET)显像评价预测患者无进展生存期(PFS)的价值。方法 43例NHL患者在ASCT前后均行18F-FDG PET/CT检查,ASCT后随访时间均>18个月。根据随访结果,将ASCT前18F-FDG PET显像阳性患者分为进展与无进展组,比较两者最大标准化摄取值(SUVmax)的平均值。采用Kaplan-Meier方法进行PFS分析,并对影响PFS与预后的一系列因素进行Cox回归分析。结果 ASCT前,20例18F-FDG PET显像阳性患者中13例出现疾病进展,其SUVmax平均值明显高于其余7例无进展者[(5.9±2.0)对(3.6±1.5),P=0.016]。ASCT前后18F-FDG PET显像为阴性和显像为阳性的患者PFS差别均有统计学意义(P<0.01)。Cox回归分析发现ASCT前后18F-FDG PET显像评价是预测PFS的最重要因素(P<0.05),且独立于其他变量。结论 ASCT前后18F-FDG PET显像评价对预测NHL预后可能有一定价值,值得更进一步研究。
Objective To evaluate F-18 fluoro-2-deoxy-D-glucose positron emission tomography（18F-FDG-PET） for the clinical outcome such as progression-free survival（PFS） in patients with non-Hodgkin＇s lymphoma（NHL） prior to and post autologous stem cell transplantation（ASCT）.Methods 18F-FDG PET/CT were performed in 43 NHL patients prior to and post ASCT,no patients were lost to follow-up earlier than 18-months from ASCT.Patients with FDG-positive before ASCT were divided into progressed or disease-free group according to the clinical outcome.The differences of maximal standard uptake value（SUVmax） were compared between two groups.The results of 18F-FDG PET pre-and post-ASCT were correlated to PFS using Kaplan-Meier survival analysis.Regression analyses were employed to test for independence of established prognostic factors.Results There were 13 of 20 patients with FDG-positive before ASCT progressed or relapsed after ASCT.In these 20 FDG-positive patients,the median SUVmax was significantly lower for the disease-free patients（3.6±1.5） as compared with progressed patients（5.9±2.0）（P=0.016）.Both pre-and post-ASCT,18F-FDG-PET findings were strongly correlated with PFS（P0.01）.The regression model showed that the predictive value of 18F-FDG-PET imaging owed its significance to the very high hazard ratio between patients with positive and negative imaging（P0.05） both pre-and post-ASCT.Conclusion 18F-FDG-PET imaging prior to and following ASCT in NHL patients may be have some value in predicting the prognosis.
出处
《世界临床药物》
CAS
2013年第5期275-279,共5页
World Clinical Drug
